USANA Health Sciences, Inc.
USNA · NYSE
12/28/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.48 | -2.16 | -0.39 | -9.37 |
| FCF Yield | 7.48% | 5.44% | 9.13% | 5.32% |
| EV / EBITDA | 5.44 | 5.80 | 5.76 | 9.42 |
| Quality | ||||
| ROIC | 5.73% | 11.10% | 14.95% | 27.40% |
| Gross Margin | 79.43% | 79.44% | 79.24% | 80.54% |
| Cash Conversion Ratio | 1.45 | 1.11 | 1.50 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.06% | -8.10% | -4.17% | 10,586,378.55% |
| Free Cash Flow Growth | -9.31% | -39.95% | -13.79% | -25.36% |
| Safety | ||||
| Net Debt / EBITDA | -1.44 | -2.58 | -2.11 | -1.15 |
| Interest Coverage | 236.03 | 355.23 | 560.49 | 2,985.82 |
| Efficiency | ||||
| Inventory Turnover | 2.52 | 3.08 | 3.09 | 2.35 |
| Cash Conversion Cycle | 123.45 | 101.88 | 101.32 | 136.25 |